Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP : a case study using protein-loaded liposomes

Webb, Cameron and Forbes, Neil and Roces, Carla B. and Anderluzzi, Giulia and Lou, Gustavo and Abraham, Suraj and Ingalls, Logan and Marshall, Keara and Leaver, Timothy J. and Watts, Julie A. and Aylott, Jonathan W. and Perrie, Yvonne (2020) Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP : a case study using protein-loaded liposomes. International Journal of Pharmaceutics, 582. 119266. ISSN 0378-5173

[img] Text (Webb-etal-IJOP-2020-Using-microfluidics-for-scalable-manufacturing-of-nanomedicines-from-bench)
Webb_etal_IJOP_2020_Using_microfluidics_for_scalable_manufacturing_of_nanomedicines_from_bench.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 3 April 2021.
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo

Download (1MB) | Request a copy from the Strathclyde author

    Abstract

    Nanomedicines are well recognised for their ability to improve therapeutic outcomes. Yet, due to their complexity, nanomedicines are challenging and costly to produce using traditional manufacturing methods. For nanomedicines to be widely exploited, new manufacturing technologies must be adopted to reduce development costs and provide a consistent product. Within this study, we investigate microfluidic manufacture of nanomedicines. Using protein-loaded liposomes as a case study, we manufacture liposomes with tightly defined physico-chemical attributes (size, PDI, protein loading and release) from small-scale (1 mL) through to GMP volume production (200 mL/min). To achieve this, we investigate two different laminar flow microfluidic cartridge designs (based on a staggered herringbone design and a novel toroidal mixer design); for the first time we demonstrate the use of a new microfluidic cartridge design which delivers seamless scale-up production from bench-scale (12 mL/min) through GMP production requirements of over 20 L/h using the same standardised normal operating parameters. We also outline the application of tangential flow filtration for down-stream processing and high product yield. This work confirms that defined liposome products can be manufactured rapidly and reproducibly using a scale-independent production process, thereby de-risking the journey from bench to approved product.